FDA okays jaw-tracking gadgets to diagnose sleep apnea
Published Date: 4/22/2026
Rule
Summary
The FDA is officially classifying devices that test sleep apnea by tracking jaw movement as Class II, meaning they have special safety rules but fewer hurdles than before. This change helps companies bring these devices to patients faster and safer, starting April 22, 2026, with the classification retroactive to January 7, 2022. Sleep apnea patients and device makers will benefit from easier access and clearer guidelines without extra costs.
Free Policy Watch
New rules are filed every week. Most people never see them.
Pick a topic. PRIA watches every federal rule and tells you when one hits your household.
Pick a topic to get started
Analyzed Economic Effects
4 provisions identified: 3 benefits, 1 costs, 0 mixed.
Device moved to Class II, speeds access
The FDA classified sleep-apnea testing devices that track jaw (mandibular) movement as Class II with special controls, effective April 22, 2026, and the classification is applicable retroactively to January 7, 2022. FDA says this lower classification will reduce regulatory burdens and enhance patient access to these devices.
Creates predicate for future devices
By classifying this device type via the De Novo process, FDA allows devices of this type to serve as predicates for future products, letting later makers use the less-burdensome 510(k) pathway instead of De Novo or PMA. That change makes it easier for companies to bring similar mandibular-movement sleep apnea devices to market.
New safety, testing, and labeling controls
The order requires special controls for these devices, including representative clinical data comparing performance to a clinical comparator, biocompatibility testing, electromagnetic/electrical safety testing, software verification and validation, and specific labeling (what is measured, warnings, interpretation guidance, and expected performance). These controls are intended to reduce risks like incorrect results or device malfunction.
Device restricted to prescription use
FDA identifies the device as a prescription device intended to aid evaluation of sleep apnea and states it is not a substitute for full polysomnography or an apnea monitor. That means you must have a prescription from a clinician to use one of these devices.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in